Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Rating of “Buy” by Analysts

Shares of Parabilis Medicines, Inc. (NASDAQ:PBLS) have received a consensus recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $41.6667.

PBLS has been the topic of several analyst reports. Guggenheim assumed coverage on Parabilis Medicines in a research report on Monday, July 6th. They set a “buy” rating and a $40.00 target price on the stock. Evercore started coverage on Parabilis Medicines in a research report on Monday, July 6th. They issued an “outperform” rating for the company. Wall Street Zen raised Parabilis Medicines to a “hold” rating in a research report on Saturday, June 20th. Lifesci Capital upgraded Parabilis Medicines to a “strong-buy” rating in a research note on Monday, July 6th. Finally, Bank of America began coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They set a “buy” rating and a $45.00 price objective on the stock.

Parabilis Medicines Stock Down 3.1%

Shares of PBLS stock opened at $29.63 on Tuesday. Parabilis Medicines has a 12 month low of $24.51 and a 12 month high of $34.47.

Insiders Place Their Bets

In related news, Director Alan Sebulsky purchased 12,500 shares of Parabilis Medicines stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the transaction, the director owned 12,500 shares in the company, valued at $250,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Guy Levy bought 500,000 shares of Parabilis Medicines stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $20.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the insider directly owned 1,027,000 shares in the company, valued at approximately $20,540,000. This trade represents a 94.88% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 530,000 shares of company stock valued at $10,723,528 in the last 90 days.